LIVIVO - Search results -

Search results

Result 1 - 10 of total 56

Search options

Article ; Online: Diverging humoral and cellular immune responses due to Omicron-a national study from the Faroe Islands.

Petersen, Maria Skaalum / Pérez-Alós, Laura / Í Kongsstovu, Sunnvør K / Eliasen, Eina Hansen / Hansen, Cecilie Bo / Larsen, Sólrun / Hansen, Jóhanna Ljósá / Bayarri-Olmos, Rafael / Fjallsbak, Jógvan Páll / Weihe, Pál / Garred, Peter

Microbiology spectrum

2023 Volume 11, Issue 6, Page(s) e0086523

Abstract: Importance: The immunity following infection and vaccination with the SARS-CoV-2 Omicron variant is poorly understood. We investigated immunity assessed with antibody and T-cell responses under different scenarios in vaccinated and unvaccinated ... ...

Abstract	Importance: The immunity following infection and vaccination with the SARS-CoV-2 Omicron variant is poorly understood. We investigated immunity assessed with antibody and T-cell responses under different scenarios in vaccinated and unvaccinated individuals with and without Omicron infection. We found that the humoral response was higher among vaccinated-naïve than unvaccinated convalescent. Unvaccinated with and without infection had comparable low humoral responses, whereas vaccinated with a second or third dose, independent of infection status, had increasingly higher levels. Only a minor fraction of unvaccinated individuals had detectable humoral responses following Omicron infection, while almost all had positive T-cell responses. In conclusion, primary Omicron infection mounts a low humoral immune response, enhanced by prior vaccination. Omicron infection induced a robust T-cell response in both unvaccinated and vaccinated, demonstrating that immune evasion of primary Omicron infection affects humoral immunity more than T-cell immunity.
MeSH term(s)	Humans ; Denmark ; Immune Evasion ; Immunity, Humoral ; Vaccination ; Immunity, Cellular ; Antibodies, Viral ; Antibodies, Neutralizing
Chemical Substances	Antibodies, Viral ; Antibodies, Neutralizing
Language	English
Publishing date	2023-11-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	2807133-5
ISSN	2165-0497 ; 2165-0497
ISSN (online)	2165-0497
ISSN	2165-0497
DOI	10.1128/spectrum.00865-23
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Increase in the Complement Activation Product C4d and the Terminal Complement Complex sC5b-9 Is Associated with Disease Severity and a Fatal Outcome in Necrotizing Soft-Tissue Infection

Morten Hedetoft / Martin Bruun Madsen / Cecilie Bo Hansen / Ole Hyldegaard / Peter Garred

Journal of Innate Immunity, Pp 1-

2021 Volume 11

Abstract: The hyperinflammatory burden is immense in necrotizing soft-tissue infection (NSTI). The complement system is a key during the innate immune response and may be a promising target to reduce the inflammatory response, potentially improving the clinical ... ...

Abstract	The hyperinflammatory burden is immense in necrotizing soft-tissue infection (NSTI). The complement system is a key during the innate immune response and may be a promising target to reduce the inflammatory response, potentially improving the clinical outcome. However, complement activation and its association to disease severity and survival remain unknown in NSTI. Therefore, we prospectively enrolled patients with NSTI and sampled blood at admission and once daily for the following 3 days. Plasma C4c, C4d, C3bc, and C3dg and the terminal complement complex (TCC) were evaluated using ELISA techniques. In total, 242 patients were included with a median age of 62 years, with a 60% male predominance. All-cause 30-day mortality was 17% (95% confidence interval [CI] 13–23) with a follow-up of >98%. C4c and C3dg were negatively correlated with Simplified Acute Physiology Score II (Rho −0.22, p < 0.001 and Rho −0.17, p = 0.01). Patients with septic shock (n = 114, 47%) had higher levels of baseline TCC than those in non-shock patients (18 vs. 14, p < 0.001). TCC correlated with the Sequential Organ Failure Assessment (SOFA) score (Rho 0.19, p = 0.004). In multivariate Cox regression analysis (adjusted for age, sex, comorbidity, and SOFA score), high baseline C4d (>20 ng/mL) and the combination of high C4d and TCC (>31 arbitrary units/mL) were associated with increased 30-day mortality (hazard ratio [HR] 3.26, 95% CI 1.56–6.81 and HR 5.12, 95% CI 2.15–12.23, respectively). High levels of both C4d and TCC demonstrated a negative predictive value of 0.87. In conclusion, we found that in patients with NSTI, complement activation correlated with the severity of the disease. High baseline C4d and combination of high C4d and TCC are associated with increased 30-day mortality. Low baseline C4d or TCC indicates a higher probability of survival.
Keywords	necrotizing soft-tissue infection ; complement ; c4d ; terminal complement complex ; sepsis ; Medicine ; R ; Internal medicine ; RC31-1245
Subject code	616
Language	English
Publishing date	2021-12-01T00:00:00Z
Publisher	Karger Publishers
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Increase in the Complement Activation Product C4d and the Terminal Complement Complex sC5b-9 Is Associated with Disease Severity and a Fatal Outcome in Necrotizing Soft-Tissue Infection.

Hedetoft, Morten / Madsen, Martin Bruun / Hansen, Cecilie Bo / Hyldegaard, Ole / Garred, Peter

Journal of innate immunity

2021 Volume 14, Issue 4, Page(s) 355–365

Abstract	The hyperinflammatory burden is immense in necrotizing soft-tissue infection (NSTI). The complement system is a key during the innate immune response and may be a promising target to reduce the inflammatory response, potentially improving the clinical outcome. However, complement activation and its association to disease severity and survival remain unknown in NSTI. Therefore, we prospectively enrolled patients with NSTI and sampled blood at admission and once daily for the following 3 days. Plasma C4c, C4d, C3bc, and C3dg and the terminal complement complex (TCC) were evaluated using ELISA techniques. In total, 242 patients were included with a median age of 62 years, with a 60% male predominance. All-cause 30-day mortality was 17% (95% confidence interval [CI] 13-23) with a follow-up of >98%. C4c and C3dg were negatively correlated with Simplified Acute Physiology Score II (Rho -0.22, p < 0.001 and Rho -0.17, p = 0.01). Patients with septic shock (n = 114, 47%) had higher levels of baseline TCC than those in non-shock patients (18 vs. 14, p < 0.001). TCC correlated with the Sequential Organ Failure Assessment (SOFA) score (Rho 0.19, p = 0.004). In multivariate Cox regression analysis (adjusted for age, sex, comorbidity, and SOFA score), high baseline C4d (>20 ng/mL) and the combination of high C4d and TCC (>31 arbitrary units/mL) were associated with increased 30-day mortality (hazard ratio [HR] 3.26, 95% CI 1.56-6.81 and HR 5.12, 95% CI 2.15-12.23, respectively). High levels of both C4d and TCC demonstrated a negative predictive value of 0.87. In conclusion, we found that in patients with NSTI, complement activation correlated with the severity of the disease. High baseline C4d and combination of high C4d and TCC are associated with increased 30-day mortality. Low baseline C4d or TCC indicates a higher probability of survival.
MeSH term(s)	Complement Activation ; Complement Membrane Attack Complex ; Female ; Humans ; Male ; Middle Aged ; Severity of Illness Index ; Soft Tissue Infections
Chemical Substances	Complement Membrane Attack Complex
Language	English
Publishing date	2021-12-14
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2454158-8
ISSN	1662-8128 ; 1662-811X
ISSN (online)	1662-8128
ISSN	1662-811X
DOI	10.1159/000520496
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6727: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Prediction of Respiratory Failure and Mortality in COVID-19 Patients Using Long Pentraxin PTX3.

Hansen, Cecilie Bo / Sandholdt, Håkon / Møller, Maria Elizabeth Engel / Pérez-Alós, Laura / Pedersen, Lise / Bastrup Israelsen, Simone / Garred, Peter / Benfield, Thomas

Journal of innate immunity

2022 Volume 14, Issue 5, Page(s) 493–501

Abstract: The course of COVID-19 is unpredictable, ranging from asymptomatic to respiratory failure and death. Prognostic biomarkers are urgently needed. We hypothesized that long pentraxin PTX3 could be a valuable plasma biomarker due to its essential role in ... ...

Abstract	The course of COVID-19 is unpredictable, ranging from asymptomatic to respiratory failure and death. Prognostic biomarkers are urgently needed. We hypothesized that long pentraxin PTX3 could be a valuable plasma biomarker due to its essential role in inflammatory processes. In a prospective hospitalized COVID-19 derivation cohort (n = 126) during the spring of 2020, we measured PTX3 within 4 days of admission. The predictive value of mechanical ventilation (MV) and 30-day mortality compared with clinical parameters and other markers of inflammation were assessed by logistic regression analysis and expressed as odds ratio (OR) with 95% confidence interval (CI). Analyses were repeated in a prospective validation cohort (n = 112) of hospitalized patients with COVID-19 treated with remdesivir and dexamethasone. Thirty-day mortality in the derivation cohort was 26.2%. In patients who died, the median PTX3 concentration upon admission was 19.5 ng/mL (IQR: 12.5-33.3) versus 6.6 ng/mL (IQR 2.9-12.3) (p < 0.0001) for survivors. After adjustment for covariates, the odds of 30-day mortality increased two-fold for each doubling of PTX3 (OR 2.03 [95% CI: 1.23-3.34], p = 0.006), which was also observed in the validation cohort (OR 1.70 [95% CI: 1.09-2.67], p = 0.02). Similarly, PTX3 levels were associated with MV. After adjustment for covariates, OR of MV was 2.34 (95% CI: 1.33-4.12, p = 0.003) in the derivation cohort and 1.64 (95% CI: 1.03-2.62, p = 0.04) in the validation cohort. PTX3 appears to be a useful clinical biomarker to predict 30-day respiratory failure and mortality risk in COVID-19 patients treated with and without remdesivir and dexamethasone.
MeSH term(s)	Biomarkers ; C-Reactive Protein/analysis ; COVID-19/drug therapy ; Dexamethasone ; Humans ; Prognosis ; Respiratory Insufficiency/diagnosis ; Respiratory Insufficiency/drug therapy ; Serum Amyloid P-Component/analysis
Chemical Substances	Biomarkers ; Serum Amyloid P-Component ; Dexamethasone (7S5I7G3JQL) ; C-Reactive Protein (9007-41-4)
Language	English
Publishing date	2022-01-21
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2454158-8
ISSN	1662-8128 ; 1662-811X
ISSN (online)	1662-8128
ISSN	1662-811X
DOI	10.1159/000521612
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6727: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Complement Activation Is Associated With Mortality in Patients With Necrotizing Soft-Tissue Infections-A Prospective Observational Study.

Kristensen, Markus Korsholm / Hansen, Marco Bo / Madsen, Martin Bruun / Hansen, Cecilie Bo / Pilely, Katrine / Hyldegaard, Ole / Garred, Peter

Frontiers in immunology

2020 Volume 11, Page(s) 17

Abstract: Aim: ...

Abstract	Aim:
MeSH term(s)	Aged ; Case-Control Studies ; Complement Activation ; Complement C3b/analysis ; Complement C4/analysis ; Fasciitis, Necrotizing/blood ; Fasciitis, Necrotizing/complications ; Fasciitis, Necrotizing/immunology ; Fasciitis, Necrotizing/mortality ; Female ; Humans ; Intensive Care Units ; Male ; Mannose-Binding Protein-Associated Serine Proteases/analysis ; Middle Aged ; Organ Dysfunction Scores ; Patient Admission ; Peptide Fragments/analysis ; Prognosis ; Prospective Studies ; Soft Tissue Infections/blood ; Soft Tissue Infections/complications ; Soft Tissue Infections/immunology ; Soft Tissue Infections/mortality ; Survival Rate
Chemical Substances	C3 beta c ; Complement C4 ; Peptide Fragments ; Complement C3b (80295-43-8) ; MASP1 protein, human (EC 3.4.21.-) ; MASP2 protein, human (EC 3.4.21.-) ; Mannose-Binding Protein-Associated Serine Proteases (EC 3.4.21.-)
Language	English
Publishing date	2020-01-31
Publishing country	Switzerland
Document type	Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2020.00017
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Short-Lived Antibody-Mediated Saliva Immunity against SARS-CoV-2 after Vaccination.

Madsen, Johannes Roth / Holm, Bettina Eide / Pérez-Alós, Laura / Bayarri-Olmos, Rafael / Rosbjerg, Anne / Fogh, Kamille / Pries-Heje, Mia Marie / Møller, Dina Leth / Hansen, Cecilie Bo / Heftdal, Line Dam / Hasselbalch, Rasmus Bo / Hamm, Sebastian Rask / Frikke-Schmidt, Ruth / Hilsted, Linda / Nielsen, Susanne Dam / Iversen, Kasper Karmark / Bundgaard, Henning / Garred, Peter

Microbiology spectrum

2023 , Page(s) e0494722

Abstract: Knowledge about the effect of vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on immunity reflected in the saliva is sparse. We examined the antibody response in saliva compared to that in serum 2 and 6 months after the ... ...

Abstract	Knowledge about the effect of vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on immunity reflected in the saliva is sparse. We examined the antibody response in saliva compared to that in serum 2 and 6 months after the first vaccination with the BNT162b2 vaccine. Four hundred fifty-nine health care professionals were included in a prospective observational study measuring antibody levels in saliva and corresponding serum samples at 2 and 6 months after BNT162b2 vaccination. Vaccinated, previously SARS-CoV-2-infected individuals (hybrid immunity) had higher IgG levels in saliva at 2 months than vaccinated, infection-naive individuals (
Language	English
Publishing date	2023-03-06
Publishing country	United States
Document type	Journal Article
ZDB-ID	2807133-5
ISSN	2165-0497 ; 2165-0497
ISSN (online)	2165-0497
ISSN	2165-0497
DOI	10.1128/spectrum.04947-22
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Waning humoral and cellular immunity after COVID-19 vaccination in patients with psoriasis treated with methotrexate and biologics: a cohort study.

Kvist-Hansen, Amanda / Pérez-Alós, Laura / Al-Sofi, Rownaq Fares / Heftdal, Line Dam / Hamm, Sebastian Rask / Møller, Dina Leth / Pries-Heje, Mia Marie / Fogh, Kamille / Hansen, Cecilie Bo / Hasselbalch, Rasmus Bo / Madsen, Johannes Roth / Armenteros, Jose Juan Almagro / Frikke-Schmidt, Ruth / Hilsted, Linda / Sørensen, Erik / Ostrowski, Sisse Rye / Bundgaard, Henning / Nielsen, Susanne Dam / Iversen, Kasper /

Zachariae, Claus / Garred, Peter / Skov, Lone

The British journal of dermatology

2023 Volume 188, Issue 5, Page(s) 661–669

Abstract: Background: mRNA-based COVID-19 vaccines have short- and long-term efficacy in healthy individuals, but their efficacy in patients with psoriasis receiving immunomodulatory therapy is less studied.: Objectives: To investigate long-term immunity after ...

Abstract	Background: mRNA-based COVID-19 vaccines have short- and long-term efficacy in healthy individuals, but their efficacy in patients with psoriasis receiving immunomodulatory therapy is less studied. Objectives: To investigate long-term immunity after COVID-19 vaccination in patients with psoriasis receiving immunomodulatory therapy. Methods: A prospective cohort study including patients (n = 123) with psoriasis receiving methotrexate (MTX) or biologics and controls (n = 226). Only mRNA-based COVID-19 vaccines administered with standard intervals between doses were investigated. Markers of immunity included SARS-CoV-2 spike glycoprotein-specific IgG and IgA, neutralizing capacity, and interferon-γ release from T cells stimulated with peptides of the SARS-CoV-2 spike glycoprotein. Results: The proportion of IgG responders was lower 6 months after vaccination in patients receiving anti-tumour necrosis factor (TNF) treatment compared with controls. Anti-TNF treatment was associated with lower IgG levels (β = -0.82, 95% confidence interval -1.38 to -0.25; P = 0.001). The median neutralizing index was lower in the anti-TNF group [50% inhibition (interquartile range [IQR] 37-89)] compared with controls [98% inhibition (IQR 96-99)]; P < 0.001. Cellular responses were numerically lowest in the anti-TNF group. Conclusions: Treatment with anti-TNF has an impact on the immunity elicited by mRNA-based COVID-19 vaccination in patients with psoriasis, resulting in a faster waning of humoral and cellular markers of immunity; however, the clinical implications are unknown.
MeSH term(s)	Humans ; Biological Products/therapeutic use ; Methotrexate/therapeutic use ; COVID-19 Vaccines ; Cohort Studies ; Prospective Studies ; Tumor Necrosis Factor Inhibitors ; COVID-19/prevention & control ; SARS-CoV-2 ; Psoriasis/drug therapy ; Immunity, Cellular ; Tumor Necrosis Factor-alpha ; Antibodies, Viral ; Vaccination
Chemical Substances	Biological Products ; Methotrexate (YL5FZ2Y5U1) ; COVID-19 Vaccines ; Tumor Necrosis Factor Inhibitors ; Tumor Necrosis Factor-alpha ; Antibodies, Viral
Language	English
Publishing date	2023-01-27
Publishing country	England
Document type	Journal Article
ZDB-ID	80076-4
ISSN	1365-2133 ; 0007-0963
ISSN (online)	1365-2133
ISSN	0007-0963
DOI	10.1093/bjd/ljad023
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.23: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis.

Journal of neuroimmunology

2023 Volume 384, Page(s) 578215

Abstract: We investigated the humoral response to the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine in patients with myasthenia gravis on or off immunosuppressants and compared this to the response in healthy individuals. The SARS-CoV-2 IgG response and neutralizing ...

Abstract	We investigated the humoral response to the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine in patients with myasthenia gravis on or off immunosuppressants and compared this to the response in healthy individuals. The SARS-CoV-2 IgG response and neutralizing capacity were measured in 83 patients (57 on immunosuppressants) and 332 healthy controls at baseline, three weeks, and two and six months after the vaccine. We found that the proportion of positive humoral response was lower in patients on immunosuppressants vs. controls at three weeks and two months (p ≤ 0.001), but not at six months post-vaccination (p = 0.379).
MeSH term(s)	Humans ; COVID-19 Vaccines ; BNT162 Vaccine ; Immunity, Humoral ; COVID-19 ; SARS-CoV-2 ; Myasthenia Gravis ; Antibodies, Viral ; Immunosuppressive Agents/therapeutic use ; Vaccination
Chemical Substances	COVID-19 Vaccines ; BNT162 Vaccine ; Antibodies, Viral ; Immunosuppressive Agents
Language	English
Publishing date	2023-09-28
Publishing country	Netherlands
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	8335-5
ISSN	1872-8421 ; 0165-5728
ISSN (online)	1872-8421
ISSN	0165-5728
DOI	10.1016/j.jneuroim.2023.578215
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1646: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: SARS-CoV-2 Natural Antibody Response Persists for at Least 12 Months in a Nationwide Study From the Faroe Islands.

Petersen, Maria Skaalum / Hansen, Cecilie Bo / Kristiansen, Marnar Fríheim / Fjallsbak, Jógvan Páll / Larsen, Sólrun / Hansen, Jóhanna Ljósá / Jarlhelt, Ida / Pérez-Alós, Laura / Steig, Bjarni Á / Christiansen, Debes Hammershaimb / Møller, Lars Fodgaard / Strøm, Marin / Andorsdóttir, Guðrið / Gaini, Shahin / Weihe, Pál / Garred, Peter

Open forum infectious diseases

2021 Volume 8, Issue 8, Page(s) ofab378

Language	English
Publishing date	2021-07-15
Publishing country	United States
Document type	Journal Article
ZDB-ID	2757767-3
ISSN	2328-8957
ISSN	2328-8957
DOI	10.1093/ofid/ofab378
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk.

Pérez-Alós, Laura / Hansen, Cecilie Bo / Almagro Armenteros, Jose Juan / Madsen, Johannes Roth / Heftdal, Line Dam / Hasselbalch, Rasmus Bo / Pries-Heje, Mia Marie / Bayarri-Olmos, Rafael / Jarlhelt, Ida / Hamm, Sebastian Rask / Møller, Dina Leth / Sørensen, Erik / Ostrowski, Sisse Rye / Frikke-Schmidt, Ruth / Hilsted, Linda Maria / Bundgaard, Henning / Nielsen, Susanne Dam / Iversen, Kasper Karmark / Garred, Peter

Nature communications

2023 Volume 14, Issue 1, Page(s) 5624

Abstract: The heterogeneity of the SARS-CoV-2 immune responses has become considerably more complex over time and diverse immune imprinting is observed in vaccinated individuals. Despite vaccination, following the emergence of the Omicron variant, some individuals ...

Abstract	The heterogeneity of the SARS-CoV-2 immune responses has become considerably more complex over time and diverse immune imprinting is observed in vaccinated individuals. Despite vaccination, following the emergence of the Omicron variant, some individuals appear more susceptible to primary infections and reinfections than others, underscoring the need to elucidate how immune responses are influenced by previous infections and vaccination. IgG, IgA, neutralizing antibodies and T-cell immune responses in 1,325 individuals (955 of which were infection-naive) were investigated before and after three doses of the BNT162b2 vaccine, examining their relation to breakthrough infections and immune imprinting in the context of Omicron. Our study shows that both humoral and cellular responses following vaccination were generally higher after SARS-CoV-2 infection compared to infection-naive. Notably, viral exposure before vaccination was crucial to achieving a robust IgA response. Individuals with lower IgG, IgA, and neutralizing antibody responses postvaccination had a significantly higher risk of reinfection and future Omicron infections. This was not observed for T-cell responses. A primary infection before Omicron and subsequent reinfection with Omicron dampened the humoral and cellular responses compared to a primary Omicron infection, consistent with immune imprinting. These results underscore the significant impact of hybrid immunity for immune responses in general, particularly for IgA responses even after revaccination, and the importance of robust humoral responses in preventing future infections.
MeSH term(s)	Humans ; Breakthrough Infections ; Reinfection ; BNT162 Vaccine ; SARS-CoV-2 ; COVID-19/prevention & control ; Vaccination ; Antibodies, Neutralizing ; Immunity ; Immunoglobulin A ; Immunoglobulin G
Chemical Substances	BNT162 Vaccine ; Antibodies, Neutralizing ; Immunoglobulin A ; Immunoglobulin G
Language	English
Publishing date	2023-09-12
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2553671-0
ISSN	2041-1723 ; 2041-1723
ISSN (online)	2041-1723
ISSN	2041-1723
DOI	10.1038/s41467-023-41342-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito